KalVista Pharmaceuticals (KALV) Misses Q2 EPS by 4c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q2 EPS of ($0.80), $0.04 worse than the analyst estimate of ($0.76).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• MongoDB stock tumbles despite earnings beat on profit-taking
• Dell Technologies (DELL) Tops Q2 EPS by $2.17, Offers Guidance